Searchable abstracts of presentations at key conferences on calcified tissues
Bone Abstracts (2019) 7 P21 | DOI: 10.1530/boneabs.7.P21

ICCBH2019 Poster Presentations (1) (226 abstracts)

Efficacy and safety of intravenous infusion of ibandronic acid in children with osteogenesis imperfecta

Shokery Awadalla

Pediatric Endocrinology, Bogota, Colombia.

Introduction: Osteogenesis Imperfecta (OI) in children has been treated with different types of biphosphonates between which Pamidronate has been the most used. Zolodronic acid has shown igual efficacy, but few studies have used ibandronic acid infusion in children.

Objective: To show efficacy and safety of ibandronic acid infusión in preventing fractures in children with OI.

Methods: 12 children with ages between 2 and 6 years were included in the study. They were receiving therapy with pamidronate infusions three days every 3 months for the last 3 years. They were switched to ibandronic acid intravenous infusión 0.15 mg/kg body weight once every three months. Vitamin D and calcium supplements were given as before. Patients were monitored for side effects during and after the infusions and also for the incidence of fractures before and after the change of therapy for 18 months

Results: No side effects were registered during or after the infusión. During the period of observation for 18 months only one patient showed a fracture as he fell from his bed, the other patients did not present any fracture. Levels of calcium and vitamin D were normal before and after the therapy.

Conclusion: Ibadndronc acid infusion is as safe and offices as pamidronate therapy in preventing fractures in children with OI. Being only one day of application instead of three, it can be easier both for patients and for parents giving the same efficacy.

Disclosure: The authors declared no competing interests.

Volume 7

9th International Conference on Children's Bone Health


Browse other volumes

Article tools

My recent searches

No recent searches.